Posted on 06/02/2009 in Pharmaceutical Company Product News Novo Nordisk and partner Sciele Pharma have launched PrandiMet tablets.
Used as a treatment for type 2 diabetes, the product is a fixed-dose combination of secretagogue repaglinide and metformin HCl.
The drug targets three abnormalities that arise in the body as a result of the condition by stimulating insulin release from the pancreas, which is dependent on the existence of functional beta cells.
According to Sciele Pharma, the combination of secretagogue repaglinide and metformin HCl that is found in the drug has been discovered to reduce A1c levels.
The company added PrandiMet should be used alongside an appropriate diet and exercise and must not be used to treat type 1 diabetes or diabetic ketoacidosis.
In December last year, Novo Nordisk and VLST Corporation announced a collaboration agreement.
The deal will see both companies developing therapeutic targets for the treatment of autoimmune and inflammatory diseases, using the latter's technology platform.Other news stories from 06/02/2009
Read more in the Zenopa News Archive
How this news is generated
|
